Clinical efficacy and cost-effectiveness of mepolizumab for COPD with type 2 inflammation
- Published on 03/03/2026
- Reading time: 8 min.
Buendía Jefferson Antonio 1, Guerrero Patiño Diana 1, Muñoz Mejia Oscar 2, Celis Preciado Carlos 3
1 https://ror.org/03bp5hc83 Research group in Pharmacology and Toxicology, Department of Pharmacology and Toxicology University of Antioquia Medellín Colombia
2 https://ror.org/037p13h95 Universidad CES Medellin Colombia
3 https://ror.org/052d0td05 Pulmonary Unit, Internal Medicine Department Hospital Universitario San Ignacio Bogota Colombia
Abstract
Background Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide. Approximately 20–40% of patients exhibit eosinophilic inflammation; a phenotype linked to higher exacerbation risk. Mepolizumab, an anti-IL-5 biologic, has shown clinical benefit in reducing exacerbations among eosinophilic COPD patients. Its cost-effectiveness, however, remains uncertain in low- and middle-income countries.
Methods A Markov...
To continue reading this article in Full-Text...
Peer-Reviewed Journals A-Z
Search | Advanced search
Get the latest news in Pneumology
Receive our newsletter to stay up to date with the latest news in Pneumology
